
Construction index shows a steady level of North American activity
ZIMonitor tracking service provides remote monitoring
'Innovation' is the recurring theme
HDMA's 2015-16 Factbook updates member financial, operational performance
Combination expands breadth of commercialization and compliance services
List includes 21 new orphan drugs, and of the 45, 15 are cold chain products
Innomar unit acquires Cameron Stewart LifeScience (CSL), provider of copay cards
Fast-growing pharma services provider will expand its global presence
Company partners with Teikoku for the latter's first marketed oncology product, and earns a milestone payment from Teva
Pharmacists (No. 2) and medical doctors (No. 3) round out top rankings
TGaS Advisors' study predicts more sales ops budgeting--but more operational challenges
Beleaguered pharma company retreats from specialty distribution
Specialty distributors handled 33% of specialty pharmaceutical distribution in 2014
Hylis Pharmacy Solutions offers a window into PBM program costs
Expanding capacities and a wider range of geographies aid life sciences developers
LifeTrack app puts shipment status in the palm of your hand
Pharma companies are looking to the data service as a potential competitive advantage
Expansion of cloud-based services includes Amazon Web Services
Company's Chartered Network is relied on for annual shipments to Africa
No immediate legislative action arises from 18-month study
Merger of New Jersey's CGS with Rondo-Pak Inc. is planned
New Internet-based delivery company wants to take the waiting time out of prescription pickups
Plans for splitting Pfizer itself are put on hold
A Community of Practice (CoP) for small- to medium-sized trial sponsors is in the offing
2015 UPS (Pain) in the Supply Chain survey finds shortcomings in contingency planning
Woodfield expands third-party logistics (3PL) services from its Florida base
US spending will rise by 34%, reaching $560-590 billion
Acquisition rebranding will build out the business' Risk Solutions unit
Higher dispensing costs and rising negative margins
While FDA tries to referee the naming conventions for biosimilars, different factions of the healthcare system weigh in with conflicting priorities